07:00 , Jul 29, 2013 |  BioCentury  |  Product Development

Tolerion's second wind

Armed with positive Phase IIa data in Type I diabetes, Tolerion Inc. is now seeking funding for a second go at developing a selective immunomodulatory approach that previously failed in multiple sclerosis. In 2011, Tolerion...
07:00 , Jul 1, 2013 |  BC Week In Review  |  Clinical News

TOL-3021: Phase II data

A blinded, dose-escalation Phase II trial in 80 adult Type I diabetics showed that all doses of once-weekly intramuscular TOL-3021 for 12 weeks improved C-peptide levels, a marker of pancreatic beta cell function, relative to...
00:45 , Jun 27, 2013 |  BC Extra  |  Clinical News

Tolerion reports Phase II data for Type I diabetes vaccine

Tolerion Inc. (Portola Valley, Calif.) said all doses of once-weekly intramuscular TOL-3021 for 12 weeks improved C-peptide levels, a marker of pancreatic beta cell function, relative to placebo in a Phase II trial to treat...
07:00 , Oct 29, 2012 |  BioCentury  |  Emerging Company Profile

Regenesance: Stopping the MAC attack

Regenesance B.V. is developing mAbs against complement 6 that may halt nerve damage and provide a better safety profile than standard of care for the orphan neurological disease myasthenia gravis. The mAbs are in lead...
08:00 , Mar 7, 2011 |  BC Week In Review  |  Company News

Bayhill autoimmune, endocrine news

Bayhill retained P2 Partners LLC to explore strategic alternatives, including a sale of company assets, partnering, or a merger or sale of the company. According to the biotech, while it has sufficient resources to start...
07:00 , Apr 19, 2010 |  BC Week In Review  |  Company News

Versartis management update

Versartis Inc. , Mountain View, Calif.   Business: Metabolic, Endocrine   Hired: Paul Westberg as SVP of business development, formerly VP of business development at Bayhill Therapeutics Inc.  ...
08:00 , Jan 18, 2010 |  BC Week In Review  |  Company News

Apthera management update

Apthera Inc. , Scottsdale, Ariz.   Business: Cancer   Hired: Mark Schwartz as president, CEO and a director, formerly president and CEO of Bayhill Therapeutics Inc.  ...
08:00 , Jan 14, 2010 |  BC Innovations  |  Targets & Mechanisms

New avenues in MS

Teams at the Karolinska Institute and The University of Tokyo have separately disclosed new targets for multiple sclerosis. Intervention in their pathways could yield new MS therapeutics if the pathways can be targeted more specifically...
07:00 , Oct 12, 2009 |  BioCentury  |  Product Development

Sizing up the Oral Alternatives for MS

Sizing up the oral alternatives for MS Two milestones were met late last month in the race to get the first oral treatment for multiple sclerosis to market: Merck KGaA submitted an NDA for its...
07:00 , Aug 10, 2009 |  BioCentury  |  Finance

Erstwhile IPO candidates

Erstwhile IPO candidates Proposed IPOs Filed Updated To be raised (A) Status (B) AutoGenomics Inc. 7/25/08 12/12/08 Up to $86.3M Mkt (diagnostic) Cumberland Pharmaceuticals Inc. 5/1/07 7/29/09 $100M Mkt (drug) Omeros Corp. 1/9/08 6/23/09 Up...